BioIVT

Have you seen our full lineup of RUO- and GMP-grade leukopaks? Featuring both normal and disease state donors from a diverse pool including over 600 HLA-typed recallable, consented donors near biotech hubs in the US and UK/EU. Take a look! https://lnkd.in/eGmqrd2f

Year-end has a way of arriving quickly. And as research teams put remaining budgets to work, demand for disease-state biospecimens can ramp up too. BioIVT has been building inventory to support research needs now and into 2027, including: • Disease- and normal-state CSF • Serum, plasma, and other blood-derived biofluids • Ethically sourced clinical tissues 𝗞𝗻𝗼𝘄 𝘄𝗵𝗮𝘁 𝘆𝗼𝘂’𝗹𝗹 𝗻𝗲𝗲𝗱? 𝗗𝗼𝗻’𝘁 𝘄𝗮𝗶𝘁 𝗳𝗼𝗿 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿-𝗲𝗻𝗱 𝗿𝘂𝘀𝗵. Plan now while availability is strong. https://hubs.ly/Q04z8Rmv0

𝗕𝗲𝗮𝘁 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿-𝗲𝗻𝗱 𝗿𝘂𝘀𝗵. We’ve built strong inventory across high-demand disease-state biospecimens to support research needs now and into 2027. But as Q4 progresses and year-end ordering ramps up, availability can change quickly. If you know what you’ll need, now is the time to secure it. Current areas of strong availability include: • Disease- and normal-state CSF • Serum, plasma, and other blood-derived biofluids • Ethically sourced clinical tissues Don’t wait until year-end demand picks up to start looking for the biospecimens your research needs. Buy now while inventory is strong. Be ready for what’s next. https://hubs.ly/Q04zTwx50

𝗬𝗼𝘂𝗿 𝟮𝟬𝟮𝟳 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗱𝗼𝗲𝘀𝗻’𝘁 𝗵𝗮𝘃𝗲 𝘁𝗼 𝘄𝗮𝗶𝘁 𝘂𝗻𝘁𝗶𝗹 𝟮𝟬𝟮𝟳. If disease-state biospecimens are part of next year’s research plans, Q4 is an opportunity to get ahead. BioIVT has been building inventory across high-demand areas, with availability including • Disease- and normal-state CSF • Blood-derived biofluids (e.g., serum & plasma) • Ethically sourced clinical tissues Put remaining 2026 budget to work and head into the new year ready to move your research forward. 𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴 𝗳𝗼𝗿 𝟮𝟬𝟮𝟳? 𝗟𝗲𝘁’𝘀 𝘀𝘁𝗮𝗿𝘁 𝗻𝗼𝘄. https://lnkd.in/eURhPRSs/?utm_campaign=DS%2526NHAMessagingEngagement&utm_source=linkedin&utm_medium=paid&utm_id=690231973&hsa_acc=503061381&hsa_cam=690231973&hsa_grp=895004873&hsa_ad=1566502383&hsa_net=linkedin&hsa_ver=3

While cellular material can be manually isolated in-house, the process requires expertise, bandwidth &/or capacity that many researchers do not have available. We can fill that gap so you can focus on your research. Our extensive #biospecimens portfolio includes readily-available, high-quality, fresh and cryopreserved cellular material from a diverse range of highly characterized donors, including purified subsets like T, NK, CD3, CD4, etc. Take a look at the options: https://lnkd.in/eWfQT5Qr

What does it take to move #NewApproachMethodologies (#NAMs) from promising research alternatives to reliable research tools? Successful implementation goes beyond just adopting new technologies. It requires careful consideration of biological relevance, reproducibility, and fit-for-purpose validation to generate meaningful and reliable data. In our latest blog, we explore these important considerations and BioIVT’s strong position in supporting researchers’ biospecimen requirements at any stage of development, from target to clinic. Read the full piece: https://hubs.ly/Q04BxQnS0